Price Chart

Executive Summary

CERO Therapeutics completed a secured financing with SRX Global, consolidating $5.67M of prior unsecured debt into a new senior secured promissory note and securing up to $6M in additional advances (total facility up to $11.67M). The company received an initial $775,665 advance (net $725,665 after legal fees) for working capital. The note matures October 15, 2026, bears 10% interest (24.99% default rate), and is secured by a pledge of 100% of the subsidiary's stock and substantially all subsidiary assets including key IP for CER-1236. The subsidiary also provided an unconditional guaranty. This is a distressed financing with a very short maturity, signaling acute liquidity needs and high refinancing risk.

Key Financial Metrics

Key Facts

• Consolidated $5,666,108.77 of prior unsecured debt into a single senior secured note with SRX Global.
• New facility provides up to $6,000,000 in additional advances, with an initial $775,665 advance funded on August 27, 2026.
• Maturity date is October 15, 2026 — only ~7 weeks from the filing date — with SRX holding unilateral extension rights for up to four 30-day periods.
• Interest rate is 10% per annum, escalating to 24.99% upon an Event of Default.
• Collateral includes 100% of the subsidiary's stock (via Pledge Agreement) and substantially all subsidiary assets including key CER-1236 patents and IP (via Asset Security Agreement).
• The subsidiary (CERo Therapeutics, Inc.) provided an absolute, unconditional guaranty of payment.
• Proceeds are for paying outstanding trade payables and working capital — no growth or pipeline funding.
• The company cannot prepay the note without SRX's consent except in a change-of-control transaction.
• Previous convertible notes (from Keystone Capital Partners and SRX) were terminated and replaced, eliminating conversion features.

Financial Impact

Up to $11.67M in total secured debt, with $5.67M already outstanding and $775,665 new cash (net $725,665). Very short maturity (Oct 15, 2026) creates acute refinancing risk.

Risk Factors

• Inability to repay or refinance the $5.67M+ by October 15, 2026, triggering default and potential loss of all subsidiary assets to SRX.
• Very short maturity (7 weeks) with no committed refinancing — extreme liquidity risk.
• Secured position of SRX over all key IP (CER-1236 patents) means equity holders could be wiped out in a default scenario.
• Negative covenants restrict additional indebtedness and liens, limiting financing alternatives.
• The company is trading on OTC with no analyst coverage and 0% bullish consensus — limited access to capital markets.

Market Snapshot

Investment Themes

Documents Analyzed

This report is based on 8 SEC documents filed with EDGAR.

US Market Status